| ||||||||||||||||
| ||||||||||||||||
— GlaxoSmithKline —Top tagsYou have executed a tag search on The Deal Newsweekly. To the right you will find a comprehensive list of stories tagged "GlaxoSmithKline." Below are the most-popular tags for The Deal Newsweekly. On the right of the page you will find a search box to dig deeper into our content.
Community
 Entries tagged "GlaxoSmithKline"Deep cleansing treatmentAs Pfizer prepares for another digestive challenge in the form of Wyeth, it is trying to unload some compounds it already has. Blackstone's there for StiefelWillkie Farr's Gregory Astrachan and others advised Stiefel on its sale to GSK. Paging Dr. SchollThe consumer-products subplot in the pharmaceutical megamergers. The big trialFrom VC to licensing, Exelixis has done every kind of deal to keep itself afloat, except one. Is an acquisition next? Where dealmaking is healthyVeteran healthcare dealmakers are moving to smaller firms, including Samantha Miller, who joined Jennerex Biotherapeutics. They need a new drugExpect Big Pharma to go shopping in biotechland, but with an eye for fire sales. This won't hurt a bitAn examination of U.S. healthcare under the Obama administration. Bridge over troubled watersCalifornia's stem cell institute has money to lend to biotech startups and, it hopes, lure VCs to the table. Diagnosis: Investment opportunityVCs have poured billions into diabetes-related startups, and the trend isn't likely to slow. A seller's marketUniversities are getting in on pharma royalty deals. Passing the pillsA new CEO takes over at Glaxo after a huge run-up of biotech licensing deals. How and when they work out is anyone's guess. | ||||||||||||||||
|
|
|
|
|
